CAR T-cell ‘cocktail’ may overcome antigen escape relapseNovember 18, 2019Lymphoma & Plasma Cell DisordersALL
Foundation launches direct-to-patient registry in multiple myelomaNovember 13, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Armored CAR T cells elicit responses in NHL patientsNovember 12, 2019DLBCLLymphoma & Plasma Cell Disorders
Survival ‘excellent’ after rituximab-bendamustine induction in transplant-eligible MCLNovember 6, 2019Lymphoma & Plasma Cell Disorders
SEER analysis reveals medication adherence factors in newly diagnosed myelomaOctober 24, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Vitamin D deficiency appears to worsen survival in Hodgkin lymphomaOctober 17, 2019Hodgkin LymphomaLymphoma & Plasma Cell Disorders
Ibrutinib linked to hypertension in B-cell malignanciesOctober 15, 2019Lymphoma & Plasma Cell Disorders
Best treatment approach for early stage follicular lymphoma is unclearOctober 9, 2019Lymphoma & Plasma Cell Disorders
Follow-up shows favorable results with acalabrutinib in MCLOctober 8, 2019Lymphoma & Plasma Cell Disorders
What is the optimal duration of maintenance in myeloma?October 8, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLLOctober 3, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Study finds no standard for treatment discontinuation in myelomaOctober 1, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Second-generation anti-BCMA CAR T-cell therapy shows promise in myeloma trialSeptember 27, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
